Literature DB >> 10719866

Calcium channel antagonist effect on in vitro meningioma signal transduction pathways after growth factor stimulation.

R L Jensen1, M Petr, R D Wurster.   

Abstract

OBJECTIVE: We have previously demonstrated that calcium channel antagonists inhibit the growth of human meningiomas in culture after stimulation with growth factors. This study examined the effects of these drugs on signaling transduction pathways in an attempt to elucidate potential mechanisms by which this growth inhibition is mediated.
METHODS: Primary cell cultures from patients with intracranial meningiomas were established. Cell growth studies were performed with inhibitors and stimulators of tyrosine kinase signal transduction. Intracellular calcium changes and inositol phosphate production were measured after growth factor exposure, with or without pretreatment by calcium channel antagonists.
RESULTS: The growth of meningiomas in culture can be inhibited by tyrosine kinase receptor inhibitors. Inhibitors and stimulators of phospholipase C can stimulate or inhibit the growth of in vitro meningiomas, respectively. Calcium channel antagonists inhibit intracellular calcium changes induced by serum and epidermal growth factor. Inositol phosphate production is increased after growth factor stimulation, and calcium channel antagonists potentiate this effect.
CONCLUSION: Calcium channel antagonists interfere with intracellular signaling pathways of cultured meningioma cells. This inhibition is unrelated to voltage-sensitive calcium channels. The findings of this project may aid in the understanding of the signal transduction mechanisms involved in growth factor-mediated meningioma proliferation and may lead to clinically relevant strategies for growth inhibition.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10719866     DOI: 10.1097/00006123-200003000-00032

Source DB:  PubMed          Journal:  Neurosurgery        ISSN: 0148-396X            Impact factor:   4.654


  9 in total

1.  In vitro growth inhibition of human colonic tumor cells by Verapamil.

Authors:  Qi-Zhen Cao; Gang Niu; Huan-Ran Tan
Journal:  World J Gastroenterol       Date:  2005-04-21       Impact factor: 5.742

Review 2.  Aberrant signaling pathways in meningiomas.

Authors:  Brian T Ragel; Randy L Jensen
Journal:  J Neurooncol       Date:  2010-09-14       Impact factor: 4.130

3.  Experimental study on the inhibitory effects of verapamil on the proliferation of meningiomas cells.

Authors:  Jian Chen; Hongtao Zhang; Heping Wang
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2007-02

4.  Molecular biology of unreresectable meningiomas: implications for new treatments and review of the literature.

Authors:  Jay Jagannathan; Rod J Oskouian; Hian Kwang Yeoh; Dwight Saulle; Aaron S Dumont
Journal:  Skull Base       Date:  2008-05

Review 5.  Chemotherapy, hormonal therapy, and immunotherapy for recurrent meningiomas.

Authors:  Chrissa Sioka; Athanassios P Kyritsis
Journal:  J Neurooncol       Date:  2008-11-21       Impact factor: 4.130

6.  Verapamil inhibits tumor progression of chemotherapy-resistant pancreatic cancer side population cells.

Authors:  Lu Zhao; Yue Zhao; Bettina Schwarz; Josef Mysliwietz; Roland Hartig; Peter Camaj; Qi Bao; Karl-Walter Jauch; Makus Guba; Joachim Walter Ellwart; Peter Jon Nelson; Christiane Josephine Bruns
Journal:  Int J Oncol       Date:  2016-05-10       Impact factor: 5.650

7.  Voltage-gated calcium channels: Novel targets for cancer therapy.

Authors:  Nam Nhut Phan; Chih-Yang Wang; Chien-Fu Chen; Zhengda Sun; Ming-Derg Lai; Yen-Chang Lin
Journal:  Oncol Lett       Date:  2017-06-22       Impact factor: 2.967

Review 8.  The prince and the pauper. A tale of anticancer targeted agents.

Authors:  Alfonso Dueñas-González; Patricia García-López; Luis Alonso Herrera; Jose Luis Medina-Franco; Aurora González-Fierro; Myrna Candelaria
Journal:  Mol Cancer       Date:  2008-10-23       Impact factor: 27.401

9.  An integrative analysis of meningioma tumors reveals the determinant genes and pathways of malignant transformation.

Authors:  José Carlos Iglesias Gómez; Adrián Mosquera Orgueira
Journal:  Front Oncol       Date:  2014-06-23       Impact factor: 6.244

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.